Analytics
Pfizer is interested in acquiring Actavis in order to avoid high US taxes
Similar proposition by Pfizer was rejected for the fourth time by AstraZeneca earlier this year.
Read moreAnalysts are anticipating market growth in 2014
RNC Pharma is forecasting the retail sector to grow by 10-12%, hospital sector – 12-15%.
Read moreUSA budget will save 250 bln USD by 2014 by switching to biosimilars
Biosimilars have been available in Europe since 2006. Novartis is currently waiting on FDA decision on its first in the US biosimilar of Neupogen.
Read moreRussian companies developed and submitted to the Minister of Health Veronika Skvortsova a proposal of rules governing studies of biosimilars
A number of Russian companies including BIOCAD, Generium, GEROPHARM, ChemRar, R-pharm, Sotex, Pharmstandard and others developed Rules for conducting studies of biosimilars.
Read moreMerck Serono will market products manufactured by Lupin
German-based Merck Serono and Indian company Lupin recently became partners. Lupin will manufacturer products that will be marketed by Merck Serono in developing markets.
Read moreRussian pharmaceutical market 2013
Since recently experts haven’t had single opinion on the volume and dynamics of the Russian pharmaceutical market as a whole as well as its main sectors. Aggregate market value in 2013 is evaluated at 750–80 bn Rbls, consisting of three major segments: retail (out-of-pocket), hospital and reimbursable drug coverage.
Retail…
Read moreNutritional supplements market in Russia reached 311 million units and 26.4 billion rubles in wholesale prices (36.3 billion rubles in retail prices) in 2013
Russian nutritional supplements grew 20% in value and 6% in volume vs. 2012. The market is dominated by domestic products (62% in value and 82% in units).
Read moreTOP-10 Pharmaceutical Manufacturers in Russia. June 2014 Rating
Russian pharmaceutical giant Pharmstandart continues to lead the rating with almost double difference from the next closest follower KRKA-Rus.
Read more